See more : Double Standard Inc. (3925.T) Income Statement Analysis – Financial Results
Complete financial analysis of Vitura Health Limited (VIT.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vitura Health Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Oil Country Tubular Limited (OILCOUNTUB.BO) Income Statement Analysis – Financial Results
- China Railway Special Cargo Logistics Co., Ltd. (001213.SZ) Income Statement Analysis – Financial Results
- Nanobiotix S.A. (NNBXF) Income Statement Analysis – Financial Results
- China Communications Construction Company Limited (1800.HK) Income Statement Analysis – Financial Results
- OTP Bank Nyrt. (OTPBF) Income Statement Analysis – Financial Results
Vitura Health Limited (VIT.AX)
About Vitura Health Limited
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia and Asia. Its brands include CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. The company was incorporated in 2018 and is based in South Yarra, Australia.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|---|
Revenue | 123.87M | 117.34M | 66.99M | 1.69M | 123.85K | 0.00 | 447.59K | 18.00K |
Cost of Revenue | 89.65M | 91.39M | 41.56M | 819.91K | 7.06K | 27.42K | 9.50K | 0.00 |
Gross Profit | 34.22M | 25.96M | 25.43M | 872.93K | 116.79K | -27.42K | 438.10K | 18.00K |
Gross Profit Ratio | 27.63% | 22.12% | 37.96% | 51.57% | 94.30% | 0.00% | 97.88% | 100.00% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 17.56M | 14.37M | 14.13M | 4.21M | 3.85M | 813.51K | 93.64K | 74.00K |
Selling & Marketing | 2.77M | 543.14K | 528.71K | 285.63K | 65.51K | 2.05M | 152.92K | -51.66K |
SG&A | 20.32M | 6.09M | 14.66M | 4.49M | 3.85M | 2.86M | 246.56K | 22.34K |
Other Expenses | 0.00 | 81.71K | 255.00K | 82.54K | 207.88K | 0.00 | 400.00 | 0.00 |
Operating Expenses | 29.35M | 6.09M | 16.19M | 8.34M | 4.24M | 2.86M | 246.16K | 22.34K |
Cost & Expenses | 119.00M | 97.48M | 57.75M | 9.16M | 4.25M | 2.89M | 255.66K | 22.34K |
Interest Income | 669.87K | 334.31K | 9.07K | 46.56K | 132.20K | 1.24K | 401.00 | 0.00 |
Interest Expense | 1.05M | 33.94K | 441.44K | 294.16K | 205.14K | 125.74K | 0.00 | 0.00 |
Depreciation & Amortization | 1.64M | 988.36K | 683.31K | 205.86K | 41.01K | 27.42K | 9.50K | 85.00K |
EBITDA | 7.08M | 20.85M | 10.87M | -486.62K | -3.74M | -2.86M | 201.43K | 62.66K |
EBITDA Ratio | 5.71% | 17.77% | 16.23% | -28.75% | -3,055.75% | 0.00% | -55.00% | 348.11% |
Operating Income | 4.87M | 19.86M | 10.19M | -3.91M | -3.83M | -2.89M | -255.66K | -22.34K |
Operating Income Ratio | 3.93% | 16.93% | 15.21% | -231.07% | -3,088.86% | 0.00% | -57.12% | -124.11% |
Total Other Income/Expenses | -302.86K | 190.54K | -177.38K | -4.21M | 175.95K | -67.29K | 447.94K | 0.00 |
Income Before Tax | 4.56M | 20.05M | 9.74M | -4.21M | -3.99M | -2.96M | 192.28K | -22.34K |
Income Before Tax Ratio | 3.68% | 17.09% | 14.55% | -248.45% | -3,221.38% | 0.00% | 42.96% | -124.12% |
Income Tax Expense | 1.31M | 6.30M | 3.73M | 220.06K | 319.55K | -43.94K | 41.93K | 0.00 |
Net Income | 3.51M | 13.81M | 6.05M | -4.05M | -3.94M | -2.91M | 150.35K | -22.34K |
Net Income Ratio | 2.84% | 11.77% | 9.03% | -239.20% | -3,179.02% | 0.00% | 33.59% | -124.12% |
EPS | 0.01 | 0.02 | 0.01 | -0.01 | -0.04 | -0.02 | 0.00 | 0.00 |
EPS Diluted | 0.01 | 0.02 | 0.01 | -0.01 | -0.04 | -0.02 | 0.00 | 0.00 |
Weighted Avg Shares Out | 569.93M | 555.20M | 482.44M | 401.69M | 91.74M | 128.75M | 128.75M | 128.75M |
Weighted Avg Shares Out (Dil) | 569.93M | 571.78M | 486.87M | 401.69M | 91.74M | 128.75M | 128.75M | 128.75M |
Source: https://incomestatements.info
Category: Stock Reports